Cilengitide
Cat. No.：YN280088
CAS No. ：188968-51-6
| 产品名称: | Cilengitide |
| CAS No.: | 188968-51-6 |
| Chemical Name: | cyclo(L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-N-methyl-L-valyl) |
| Synonyms: | 西仑吉肽; EMD 121974 |
| 分子量: | 588.66 |
| 分子式: | C₂₇H₄₀N₈O₇ |
| SMILES: | O=C(NCC(N[C@H](C(N[C@H](CC1=CC=CC=C1)C(N([C@H]2C(C)C)C)=O)=O)CC(O)=O)=O)[C@H](CCCNC(N)=N)NC2=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Cilengitide (EMD 121974) 是一种有效的选择性整合素ανβ3和ανβ5抑制剂。Cilengitide 抑制 ανβ3和 ανβ5与玻连蛋白结合，IC50值分别为 4 和 79 nM。 |
| IC50和靶点: | [{name:"αvβ3:4 nM (IC50, αvβ3-Vitronectin interaction)"},{name: "αvβ5:79 nM (IC50, αvβ5-Vitronectin interaction)"},{name: "αvβ3:0.61 nM (IC50, )"},{name: "αvβ5:8.4 nM (IC50, )"},{name: "α5β1:14.9 nM (IC50, )'}, 'STAT3'] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Chatterjee, S., Matsumura, A., Schradermeier, J., et al.Human malignant glioma therapy using anti-αVβ3 integrin agentsJ. Neurooncol.46(2),135-144(2000)
Yamada, S., Bu, X.-Y., Khankaldyyan, V., et al.Effect of the angiogenesis inhibitor cilengitide (EMD 121974) on glioblastoma growth in nude miceNeurosurgery59(6),1304-1312(2006)
